Loading organizations...
§ Private Profile · Barcelona, Catalonia, Spain
Medical device and biotech company developing urology solutions for kidney health, urinary tract conditions, and stone management.
Founded in 2012 by Rosendo Garganta, Devicare is a Barcelona, Spain-based medical device and biotechnology company developing urological treatments, dietary supplements, and urinary hygiene products for patients managing kidney stones and urinary tract conditions. The organization operates a direct-to-consumer business model across Spain, Italy, and Türkiye, offering personalized online healthcare consultations alongside its Lit-Control, Urogelus, and Nodorin product lines to aid in post-surgical recovery. Financially, the company generates approximately $2.73 million in annual revenue alongside $341,000 in EBITDA. Devicare has secured $8.83 million in total funding, including a January 2021 $3 million Series A round led by Advanced MedTech Holdings, with additional venture backing from the European Investment Fund, EMESA SL, and Equity4Good. The restructured corporate board features independent members associated with industry peers like Cardiolink, M4 Pharma, Ship2B Ventures, and Dornier MedTech.
Devicare has raised $8.8M across 4 funding rounds.
Devicare has raised $8.8M in total across 4 funding rounds.
Devicare has raised $8.8M in total across 4 funding rounds.
Devicare's investors include Abel Ang, Juan Knuth, Ship2B, Avançsa, Institut Catal de Finances, EMESA Corporación Empresarial.
Devicare has raised $8.8M across 4 funding rounds. Most recently, it raised $3.0M Series A in January 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 7, 2021 | $3M Series A | Abel ANG | Juan Knuth, Ship2B | Announced |
| Dec 22, 2017 | $2.4M Debt Financing | Avançsa | — | Announced |
| Sep 6, 2017 | $160K Debt Financing | Institut Catal DE Finances | — | Announced |
| May 5, 2017 | $3.3M Seed | — | Juan Knuth, Emesa Corporación Empresarial | Announced |